Dr. Rubenstein is an internationally recognized authority on the research and treatment of patients with primary and secondary CNS lymphoma. He has led or co-led multiple innovative multi-center phase I and II clinical trials that have impacted clinical management guidelines, including studies of novel induction strategies, immunomodulatory drugs, intraventricular rituximab therapy and dose intensive consolidation. He has led multiple studies on the biology of CNS lymphoma involving tumor diagnostic specimens, preclinical models as well as pioneering studies using novel technologies to gain insights into the brain tumor microenvironment. His studies on CNS lymphoma have been consistently published in high impact journals for nearly two decades and he has been the principal investigator of multiple NCI grants focused on this disease. He has mentored ~40 trainees, many of whom are now focused on the treatment of lymphoma patients in the academic setting.